Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension

Hypertension Research

Volumn 33, Issue 3, 2010, Pages 236-242

  Fogari, Roberto ^a   Zoppi, Annalisa ^a   Corradi, Luca ^a   Preti, Paola ^a   Mugellini, Amedeo ^a   Lazzari, Pierangelo ^a   Derosa, Giuseppe ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Blood pressure; Overweight; Weight loss

Indexed keywords

ALDOSTERONE; LEPTIN; RENIN; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BODY MASS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL COUNSELING; OBESITY; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

AGED; ALDOSTERONE; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIET, REDUCING; FEMALE; HUMANS; HYPERTENSION; INSULIN; LEPTIN; MALE; MIDDLE AGED; OVERWEIGHT; PROSPECTIVE STUDIES; RENIN; WEIGHT LOSS;

EID: 77749270828     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.220     Document Type: Article

References (72)

1. Burton BT, Foster WR, Hirsch J, Van Itallie TB. Health implications of obesity: an NIH Consensus Development Conference. Int J Obes 1985; 9: 155-170.
2. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003; 115 (8A): 37S-41S.
3. Williams PT, Hoffman K, La I. Weight-related increases in hypertension, hypercholes-terolemia and diabetes risk in normal weight male and female runners. Arterioscler Thromb Vasc Biol 2007; 27: 1811-1819.
4. Expert panel on the identification evaluation treatment of overweight in adults. Clinical guidelines on the Identification, Evaluation and Treatment in overweight and obesity in adults: executive summary. Am J Clin Nutr 1998; 64: 899-917.
5. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002; 23: 706-713.
6. Mc Lellan F. Obesity rising to alarming levels around the world. Lancet 2002; 359: 1412.
7. Bray GA. Epidemiology, risks and pathogenesis of obesity. Meat Sci 2005; 71: 2.
8. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel-Smoller S, Hong Y, American Heart Association Statistics Committee Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
9. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States 1999-2004. JAMA 2006; 295: 1549-1555.
10. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. J Am Med Assoc 1999; 282: 1523-1529.
11. Guidelines Sub-Committee. 1999 World Health Organization/International Society of Hypertension. Guidelines for the management of Hypertension. J Hypertens 2003; 21: 1011-1053.
12. Richards RJ, Thakur V, Reisin E. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment. J Hum Hypertens 1996; 10 (Suppl 3): S59-S64.
13. Sharma AM, Engeli S, Pischon T. New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertebs Rep 2001; 3: 152-156.
14. Rocchini AP. Obesity hypertension. Am J Hypertens 2002; 15: 50S-52S.
15. Jonk AM, Houben AJ, de Jongh RT, Serné EH, Schaper NC, Stehouwer CD. Micro-vascular function in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology 2007; 22: 252-260.
16. Serné EH, de Jongh RT, Eringa EC, IJzerman RG, Stehouwer CD. Microvascular dysfunction: a potential patophysiological role in the metabolic syndrome. Hypertension 2007; 50: 204-211.
17. Stapleton PA, James ME, Goodwill AG, Frisbee JC. Obesity and vascular dysfunction. Pathophysiology 2008; 15: 79-89.
18. Reisin E, Abel R, Modan M, Silverberg DS, Eliahou HE, Modan B. Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978; 298: 1-6.
19. Dornfeld LP, Maxwell MH, Vaks AU, Schroth P, Tuck ML. Obesity and hypertension: long-term effects of weight reduction on blood pressure. Int J Obes 1985; 9: 381-389.
20. Schotte DE, Stunkard AJ. The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med 1990; 150: 1701-1704.
21. Davis BR, Blaufox MD, Oberman A, Wassertheil-Smoller S, Zimbaldi N, Cutler JA, Kirchner K, Langford HG. Reduction in long-term antihypertensive medication requirements: effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1993; 153: 1773-1782.
22. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20: 1873-1878.
23. Stamler R, Stamler J, Gosch FC, Civinelli J, Fishman J, McKeever P, McDonald A, Dyer AR. Primary prevention of hypertension by nutritional-hygienic means: final report of a randomized, controlled trial. JAMA 1989; 262: 1801-1807.
24. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of hypertension Prevention, phase II. Arch Intern Med 1997; 157: 657-667.
25. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35: 544-549.
26. Moore LL, Visioni A, Qureshi M, Bradlee L, Ellison C, D'Agostino R. Weight loss in overweight adults and the long-term risk of hypertension. The Framingham Study. Arch Intern Med 2005; 165: 1298-1303.
27. Winnicki M, Bonso E, Dorigatti F, Longo D, Zaetta V, Mattarei M, D'Este D, Laurini G, Pessina AC, Palatini P. Effect of body weight loss on blood pressure after 6 years of follow-up in stage 1 hypertension. Am J Hypertens 2006; 19: 1103-1109.
28. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762. (Pubitemid 47356612)
29. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998; 6 (Suppl 2): 51S-209S.
30. Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005; 7: 47-55.
31. Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholester-olemia prescribed a standardized diet. Clin Ther 2003; 25: 1107-1122.
32. Derosa G, Mugellini A, Ciccarelli L, Rinaldi A, Fogari R. Effects of Orlistat, Simvastatin, and Orlistat+Simvastatin in obese patients with hypercholesterolemia: A randomized, open-label trial. Curr Ther Res 2002; 63: 621-633.
33. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr Metab 2004; 17: 222-229.
34. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, Mikhailidis DP, Elisaf MS. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercho-lesterolaemia. Curr Med Res Opin 2008; 24: 1919-1929.
35. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
36. Misra A, Garg A. Leptin: its receptor and obesity. J Invest Med 1996; 44: 540-548.
37. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, Milas NC, Mattfeldt-Beman M, Belden L, Bragg C, Millstone M, Raczynski J, Brewer A, Singh B, Cohen J, Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II The Hypertension Prevention Research Group. Ann Intern Med 2001; 134: 1-11.
38. Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, Zimbaldi N, Hawkins CM. Pharmacologic and nutritional treatment of mild hypertensives: changes in cardiovascular risk status. Ann Intern Med 1990; 112: 89-95.
39. Langford HG, Davis BR, Blaufox D, Oberman A, Wassertheil-Smoller S, Hawkins M, Zimbaldi N. Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group. Hypertension 1991; 17: 210-217.
40. Anderssen S, Holme I, Urdal P, Hjermann I. Diet and exercise intervention have favourable effects on blood pressure in mild hypertensives: the Oslo Diet and Exercise Study (ODES). Blood Press 1995; 4: 343-349.
41. Masuo K, Mikami H, Ogihara T, Tuck ML. Different mechanisms in weight-loss induced blood pressure reduction between a low caloric diet and an aerobic exercise. J Hypertens 2002; 20 (Suppl 4): S204.
42. Staessen J, Fagard R, Amery A. The relationship between body weight and blood pressure. J Human Hypertens 1988; 2: 207-217.
43. Ebrahim D, Smith GD. Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. J Public Health Med 1998; 20: 441-448.
44. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure. A meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878-884.
45. Bonner G. Hyperinsulinemia, insulin resistance and hypertension. J Cardiovasc Pharmacol 1994; 24 (Suppl 2): S39-S49.
46. Osei K. Insulin resistance and systemic hypertension. Am J Cardiol 1999; 84: 33J-36J.
47. Genuth SM. Insulin secretion in obesity and diabetes: an illustrative case. Ann Intern Med 1977; 87: 714-716.
48. Tuck ML, Sowers J, Dornfield L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity and aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933.
49. Reisin E, Foohlich ED. Effect of weight reduction on arterial pressure. J Chronic Dis 1982; 35: 887-891.
50. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001; 79: 20-21.
51. Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Palumbo G, Patalano A, Rizzoni D, Rossi E, Pessina AC, Mantero F, Primary Aldosteronism Prevalence in hYpertension Study Investigators. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93: 2566-2571.
52. Van Harmelen V, Ariapart P, Hoffstedt J, Lundkvist I, Bringman S, Arner P. Increased adipose angiotensinogen gene expression in human obesity. Obes Res 2000; 8: 337-341.
53. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation 1997; 96: 3423-3429.
54. Rossi GP, Sticchi D, Giuliani L, Bernante P, Zavattiero S, Pessina AC, Nussdorfer GG. Adiponectin receptor expression in the human adrenal cortex and aldosterone-produ-cing adenomas. Int J Mol Med 2006; 17: 975-980.
55. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralcorticoid receptor in corticosteroid-induced adipogenesis. FASEBJ 2007; 21: 2185-2194.
56. Eggena P, Sowers JR, Maxwell MH, Barrett JD, Golub MS. Hormonal correlates of weight loss associated with blood pressure reduction. Clin Exp Hypertens 1991; 13: 1447-1456.
57. Harp JB, Henry SA, Di Girolamo M. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes Res 2002; 10: 985-990.
58. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.
59. Young JB, Mullen D, Landsberg L. Caloric restriction lowers blood pressure in the spontaneously hypertensive rat. Metabolism 1978; 27: 1711-1714.
60. Jung RT, Shetty PS, Barrand M, Callingham BA, James WPT. Role of catecholamines in hypotensive response to dieting. Br Med J 1979; 1: 12-13.
61. Shuldiner AR, Yang R, Gong DW. Resistin, obesity and insulin resistance: the emerging role of the adypocyte as an endocrine organ. N Engl J Med 2001; 345: 1345-1346.
62. Eringa EC, Bakker W, Smulders YM, Serné EH, Yudkin JS, Stehouwer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 2007; 14: 389-402.
63. Luo JD, Zhang GS, Chen MS. Leptin and cardiovascular diseases. Ti m e l y To p M e d Cardiovasc Dis 2005; 9: E34.
64. Uçkaya G, Ozata M, Sonmez A, Kinalp C, Eyileten T, Bingol N, Koc B, Kocabalkan F, Ozdemir IC. Plasma leptin levels strongly correlate with plasma renin activity in patients with essential hypertension. Horm Metab Res 1999; 31: 435-438.
65. Barba G, Russo O, Siani A, Iacone R, Farinaro E, Gerardi MC, Russo P, Della Valle E, Strazzullo P. Plasma leptin and blood pressure in men: graded association independent of body mass and fat pattern. Obes Res 2003; 11: 160-166.
66. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension 2003; 41: 1072-1079. (Pubitemid 36548605)
67. Guha PK, Villareal D, Reams GP, Freeman RH. Role of leptin in the regulation of body fluid and pressures. Am J Ther 2003; 10: 211-218.
68. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996; 81: 4406-4413.
69. Reseland JE, Anderssen SA, Solvoll K, Hjermann I, Urdal P, Holme I, Drevon CA. Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutr 2001; 73: 240-245.
70. Itoh K, Imai K, Masuda T, Abe S, Tanaka M, Koga R, Itoh H, Matsuyama T, Nakamura M. Relationship between changes in serum leptin and blood pressure after weight loss. Hypertens Res 2002; 25: 881-886.
71. German J, Kim F, Schwartz GJ, Havel PJ, Rhodes CJ, Schwartz MW, Morton GJ. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology 2009; 150: 4502-4511.
72. Niswender KD, Schwartz MW. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocri-nol 2003; 24: 1-10.